First Line Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Recommendations From a Canadian...

Area of Science:

• Hematology
• Oncology
• Clinical Practice Guidelines

Background:

• Effective multiple myeloma (MM) therapies prompt re-evaluation of first-line autologous stem cell transplantation (ASCT).
• High-risk MM patients still face suboptimal treatment outcomes.
• Rapidly evolving MM treatment landscape necessitates updated guidance.

Purpose of the Study:

• To propose consensus recommendations for first-line treatment of transplant-eligible multiple myeloma (TEMM).
• To provide guidance for physicians and patients on TEMM management.
• To address key aspects of TEMM treatment, including eligibility, induction, ASCT, and maintenance.

Main Methods:

• Development of consensus recommendations by the Canadian Consensus Guideline Consortium (CGC).
• Focus on current best practices, including quadruplet induction therapy with anti-CD38 antibodies.
• Comprehensive review of ASCT eligibility, induction, mobilization, conditioning, consolidation, maintenance, high-risk populations, adverse events, response assessment, and relapse monitoring.

Main Results:

• Quadruplet induction therapy with an anti-CD38 antibody, proteasome inhibitor, and immunomodulatory drug before ASCT is the leading strategy for TEMM.
• This approach aims for deep and sustained responses.
• Recommendations cover the full spectrum of TEMM care, including special considerations for high-risk disease.

Conclusions:

• The proposed guidelines offer a framework for optimizing first-line TEMM treatment.
• The CGC will periodically review and update these recommendations based on new evidence.
• These guidelines aim to improve outcomes for patients with transplant-eligible multiple myeloma.